Desloratadine

Cat. No.: HY-B0539
CAS No.: 100643-71-8
Molecular Formula: C₁₉H₁₉ClN₂
Molecular Weight: 310.82
Target: Histamine Receptor
Pathway: GPCR/G Protein; Immunology/Inflammation
Storage:

- Powder: -20°C 3 years, 4°C 2 years
- In solvent: -80°C 6 months, -20°C 1 month

Solvent & Solubility

In Vitro

DMSO: 25 mg/mL (80.43 mM; Need ultrasonic)
H₂O: < 0.1 mg/mL (insoluble)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>Mass (1 mg)</th>
<th>Mass (5 mg)</th>
<th>Mass (10 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td></td>
<td>3.2173 mL</td>
<td>16.0865 mL</td>
<td>32.1730 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td></td>
<td>0.6435 mL</td>
<td>3.2173 mL</td>
<td>6.4346 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td></td>
<td>0.3217 mL</td>
<td>1.6086 mL</td>
<td>3.2173 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (8.04 mM); Clear solution

2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (8.04 mM); Clear solution

3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (8.04 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Desloratadine(Sch34117) is a potent antagonist for human histamine H1 receptor used to treat allergies. Target: Histamine H1 Receptor. Desloratadine binds to the human H1 receptor with Ki value of 0.87 nM in displacing tritiated mepyramine. Desloratadine (100 nM to 10 μM) inhibits both IgE-mediated and non-IgE-mediated generation of the cytokines IL-4 and IL-13 by human basophils. Desloratadine (300 nM to 100 μM) inhibits both IgE and non-IgE-mediated histamine release from human peripheral blood basophils. Desloratadine (0.1 μM to 10 μM) is also shown
to inhibit platelet-activating factor-induced eosinophil chemotaxis and TNF-α-induced eosinophil adhesion in eosinophils obtained from patients with allergic rhinitis or allergic asthma [1]. Desloratadine (1 μM-10 μM) dose-dependently inhibits the release of histamine and LTC4 from human basophils. Desloratadine (0.1 μM-10 μM) dose-dependently inhibits IL-13 secretion from basophils activated with IL-3 and PMA from human basophils. Desloratadine (10 μM) pretreatment results in a substantial decrease of the induced cytokine message in cultured basophils. Desloratadine (10 μM) pretreatment causes approximately an 80% reduction in the IL-4 message accumulated with anti-IgE activation in cultured basophils. Desloratadine (10 μM) also inhibits the histamine and IL-4 protein secreted into the supernatants of cultured basophils [2]. [3H]Desloratadine binds to the human histamine H1 receptor expressed in CHO cells with Kd of 1.1 nM. Desloratadine is 52, 57, 194, and 153 times more potent than cetirizine, ebastine, fexofenadine, and loratadine, respectively, in competition-binding studies [3].

REFERENCES

